Navigation Links
VirtualScopics Reports Record Revenue
Date:7/8/2009

ROCHESTER, N.Y., July 8 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a provider of quantitative imaging for clinical trials, today announced revenues for the second quarter ended June 30, 2009 exceeded $2.5 million, representing a greater than 45% increase over the comparable period in 2008.

"We are extremely pleased to deliver another quarter of record revenue growth," stated Jeff Markin, President and Chief Executive Officer of VirtualScopics, Inc. "Our strong second quarter coupled with our solid financial performance in the first quarter, has resulted in top line growth of nearly 40% for the first six months of 2009." He added, "The continued demand we're seeing from our customers gives us confidence that we are on track to meet our financial targets for the remainder of 2009."

VirtualScopics plans to report its complete second quarter 2009 financial results on Wednesday, August 12, 2009. Jeff Markin and Molly Henderson, VirtualScopics' Chief Business and Financial Officer, will provide a business update and discuss the second quarter results during the conference call on Thursday, August 13, 2009 at 11:00 a.m. EDT.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards in 2009, the risk that the Company won't meet the 2009 financial targets and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov.

    CONTACT:  Company Contact:
              Molly Henderson
              Chief Business and Financial Officer
              500 Linden Oaks
              Rochester, New York 14625
              (585)249.6231


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Announces $4.35 Million Private Placement
2. VirtualScopics Backlog Exceeds a Record $20 Million
3. VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting
4. VirtualScopics Reports Second Quarter 2008 Results
5. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
6. VirtualScopics to Present at Two Upcoming Investor Conferences
7. VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit
8. VirtualScopics Backlog Rises to a Record $27 Million
9. VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference
10. VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq
11. VirtualScopics Scientists to Present at International Society for Magnetic Resonance in Medicine 17th Scientific Meeting and Exhibition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... use and find themselves having to wait longer to access the treadmills. It’s a ... New Year’s resolutions to lose weight and get in shape by joining gyms, starting ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Stuart Bentkover, ... technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. Bentkover ... unmatched results. , Developed by Cynosure, the PicoSure has been approved by the Food ...
(Date:2/5/2016)... Pekin, IL (PRWEB) , ... February 05, 2016 , ... ... in disguised form as a dream. A hallmark feature of patients with eating disorders ... and needs. The eating disorder behaviors and obsessions are regarded as maladaptive means for ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, ... a continuing medical education (CME) event presented by the Association for Comprehensive Care ... first for ACCORD, whose mission is to provide education, tools, and resources to ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... WILLIAMSBURG, Va. , Feb. 5, 2016  ivWatch, a ... a Virginia Outstanding STEM Award granted by Governor Terry ... for Science Innovation on February 25th at an event to ... . The STEM award honors professionals and business that ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... MILTON, Ontario , Feb. 5, 2016  Aralez ... business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada ... of POZEN and shareholders of Tribute. The combined company ... specialty pharmaceutical company with operations in Canada ... the United States . Under the terms ...
(Date:2/5/2016)...  Venice,s newest laser clinic, Physicians Advanced ... kind in the area and specializes in the ... The physician-owned and operated laser clinic is taking ... with its revitalizing skin care approach, unprecedented eVisit ... technology. http://photos.prnewswire.com/prnh/20160204/329957 --> ...
Breaking Medicine Technology: